Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
Elisia Villemure, Robert L. Yauch(Gene Therapy Laboratory)
Cited by 11
Related Papers
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
|Nature Communications|2022|125
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
|Research Square|2022|2